Stockreport

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

IN8bio, Inc.  (INAB) 
PDF Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (?d) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to onl [Read more]